骨髓增生異常症候群 (MDS) 藥物市場、機會、成長動力、產業趨勢分析與預測，2024-2032

Myelodysplastic Syndrome (MDS) Drugs Market, Opportunity, Growth Drivers, Industry Trend Analysis and Forecast, 2024-2032

出版日期: 2024年08月19日 | 出版商:

Global Market Insights Inc. | 英文 130 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2023 年，全球骨髓增生異常症候群(MDS) 藥物市值為28 億美元，預計2024 年至2032 年複合年成長率為8%。在老化人口中，導致對有效治療的需求增加。例如，美國癌症協會報告稱，美國每年診斷出約 10,000 例新的 MDS 病例，其中主要是 60 歲以上的個體。此外，診斷技術的進步促進了MDS的早期檢測，為及時有效的治療鋪平了道路。這反過來又增加了對 MDS 藥物的需求。

MDS 藥物的技術進步，加上診斷技術的增強，正在推動市場的顯著成長。例如，美國國家癌症研究所 (NCI) 指出，在過去 5 年中，使用新一代定序 (NGS) 進行 MDS 診斷的情況每年增加 20%。這項尖端技術可以精確定位與 MDS 相關的特定基因突變，從而促進量身定做的治療計劃。此外，《臨床腫瘤學雜誌》上的一項研究強調，由於這些先進的工具，早期 MDS 診斷率提高了 30%。這種及時檢測至關重要，可以採取干涉措施來減緩疾病進展並提高患者治療效果。因此，隨著診斷方法的進步，對MDS藥物的需求勢將會增加。增強的診斷不僅可以提高治療效果，還可以透過識別更多適合標靶治療的患者來擴大市場。

MDS 藥物產業根據藥物類型、給藥途徑、藥物、癌症類型、年齡層、最終用戶和地區進行分類。

市面上的藥物類型分為低甲基化藥物、免疫療法藥物、抗貧血藥物和血小板生成素受體激動劑。低甲基化藥物領域預計將以 15 億美元的收入領先，並在整個預測期內保持其主導地位。去甲基化藥物，如阿扎胞苷 (Vidaza) 和地西他濱 (Dacogen)，是 MDS 治療的基礎，可顯著提高存活率。例如，《柳葉刀腫瘤學》發表的臨床研究表明，阿札胞苷比傳統治療方法可將總存活期延長多達 9.6 個月。鑑於其經過驗證的功效和持續的創新，低甲基化藥物將繼續推動 MDS 藥物市場。

市場將藥物類型分為品牌藥和學名藥。到 2032 年，品牌藥物市場預計將達到 35 億美元。這些藥物旨在促進造血、減少輸血依賴性並減緩疾病進展。例如，FDA 批准的 Vidaza（阿扎胞苷）和 Dacogen（地西他濱）是著名的低甲基化藥物，凸顯了品牌市場的成長軌跡。

美國骨髓增生異常綜合症藥物產業在 2023 年創造了 120 萬美元的收入。促成美國領先的因素包括該疾病的高盛行率、最先進的醫療基礎設施以及大量的醫療支出。就背景而言，白血病和淋巴瘤協會報告稱，從 2015 年到 2019 年，美國平均每年新增 15,529 例 MDS 病例，同期病例總數為 77,646 例。

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
- 歐洲其他地區
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 12 章：公司簡介

Amgen Inc.
Astex Pharmaceuticals, Inc.
Bristol-Myers Squibb Company (Celgene Corporation)
Cipla Limited
Dr. Reddy's Laboratories Inc.
Hikma Pharmaceuticals PLC
Johnson and Johnson Services, Inc.
Lupin Limited
Otsuka America Pharmaceutical, Inc.
Pfizer, Inc.
Sandoz
Shilpa Medicare Limited
Sun Pharmaceutical Industries, Inc.
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd

簡介目錄

Product Code: 10852

The Global Myelodysplastic Syndrome (MDS) Drugs Market was valued at USD 2.8 billion in 2023 and is projected to grow at an 8% CAGR from 2024 to 2032. This dynamic growth is primarily driven by the rising incidence of MDS, especially among the aging population, leading to heightened demand for effective treatments. For instance, the American Cancer Society reports that the U.S. sees approximately 10,000 new MDS cases diagnosed annually, predominantly in individuals over 60. Consequently, there's a notable uptick in the adoption of MDS drugs. Furthermore, advancements in diagnostic techniques have bolstered early MDS detection, paving the way for timely and effective treatments. This, in turn, amplifies the demand for MDS drugs.

Technological advancements in MDS drugs, coupled with enhanced diagnostic techniques, are propelling significant market growth. For instance, the National Cancer Institute (NCI) notes a 20% annual increase over the past five years in the use of next-generation sequencing (NGS) for MDS diagnosis. This cutting-edge technology pinpoints specific genetic mutations tied to MDS, facilitating tailored treatment plans. Moreover, a study in the Journal of Clinical Oncology highlighted a 30% boost in early MDS diagnosis rates thanks to these advanced tools. Such timely detection is paramount, allowing for interventions that can decelerate disease progression and elevate patient outcomes. Thus, as diagnostic methods advance, the demand for MDS drugs is poised to rise. Enhanced diagnostics not only elevate treatment efficacy but also expand the market by identifying more patients suited for targeted therapies.

The MDS drugs industry is classified based on drug type, route of administration, medication, cancer type, age group, end-user, and region.

The market categorizes drug types into hypomethylating agents, immune therapy drugs, anti-anemia, and thrombopoietin receptor agonists. The hypomethylating drugs segment is projected to lead with a revenue of USD 1.5 billion, maintaining its prominence throughout the forecast period. Hypomethylating agents, like azacitidine (Vidaza) and decitabine (Dacogen), are foundational to MDS therapy, significantly boosting survival rates. For instance, The Lancet Oncology published that clinical studies show azacitidine extends overall survival by up to 9.6 months over conventional treatments. Given their proven efficacy and ongoing innovations, hypomethylating agents will continue to drive the MDS drug market.

The market divides medication types into branded and generic drugs. The branded segment is on track to hit USD 3.5 billion by 2032. Central to MDS treatment, branded medications offer targeted therapies tailored to individual needs. These drugs aim to boost hematopoiesis, reduce transfusion dependence, and slow disease progression. For instance, FDA-approved Vidaza (azacitidine) and Dacogen (decitabine) are prominent hypomethylating agents, underscoring the branded market's growth trajectory.

The U.S. Myelodysplastic Syndrome Drugs Industry generated USD 1.2 million in revenue in 2023. This dominance is expected to continue growing during the analysis period. Factors contributing to the U.S.'s leadership include a high prevalence of the disease, a state-of-the-art healthcare infrastructure, and substantial healthcare spending. For context, The Leukemia and Lymphoma Society reported an average of 15,529 new MDS cases annually in the U.S. from 2015 to 2019, totaling 77,646 cases over that span.

Chapter 1 Methodology and Scope

1.1 Market scope and definitions
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360° synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in drug development
  - 3.2.1.2 Improved diagnostic techniques
  - 3.2.1.3 Growing disease awareness initiatives
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 High cost of treatment
  - 3.2.2.2 Competition from alternative treatments
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Type, 2021-2032 ($ Mn)

5.1 Key trends
5.2 Hypomethylating drugs
5.3 Immune therapy drugs
- 5.3.1 Immunomodulatory drugs
- 5.3.2 Immunosuppressive drugs
5.4 Antianemics drugs
5.5 Thrombopoietin receptor agonists

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2021-2032 ($ Mn)

6.1 Key trends
6.2 Oral
6.3 Parenteral

Chapter 7 Market Estimates and Forecast, By Cancer Type, 2021-2032 ($ Mn)

7.1 Key trends
7.2 Refractory anemia with excess blasts (RAEB)
7.3 Refractory cytopenia with multilineage dysplasia (RCMD)
7.4 Refractory cytopenia with multilineage dysplasia and ringed sideroblasts (RCMD-RS)
7.5 Other cancer types

Chapter 8 Market Estimates and Forecast, By Medication, 2021-2032 ($ Mn)

8.1 Key trends
8.2 Branded
8.3 Generic

Chapter 9 Market Estimates and Forecast, By Age Group, 2021-2032 ($ Mn)

9.1 Key trends
9.2 Above 80
9.3 70-79
9.4 60-69
9.5 50-59
9.6 40-49
9.7 Below 40

Chapter 10 Market Estimates and Forecast, By End-user, 2021-2032 ($ Mn)

10.1 Key trends
10.2 Healthcare providers
- 10.2.1 Hospitals
- 10.2.2 Specialty clinics
10.3 Patients
10.4 Other end-users

Chapter 11 Market Estimates and Forecast, By Region, 2021-2032 ($ Mn)

11.1 Key trends
11.2 North America
- 11.2.1 U.S.
- 11.2.2 Canada
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 France
- 11.3.4 Spain
- 11.3.5 Italy
- 11.3.6 Netherlands
- 11.3.7 Rest of Europe
11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 South Korea
- 11.4.6 Rest of Asia Pacific
11.5 Latin America
- 11.5.1 Brazil
- 11.5.2 Mexico
- 11.5.3 Argentina
- 11.5.4 Rest of Latin America
11.6 Middle East and Africa
- 11.6.1 Saudi Arabia
- 11.6.2 South Africa
- 11.6.3 UAE
- 11.6.4 Rest of Middle East and Africa